Absynth is developing vaccines and antibodies to prevent and treat bacterial infections with a distinctive technology platform for identifying proprietary antigens that harness the immune system more effectively than other antigens, to stimulate a host protective response. Antimicrobial resistance constitutes a serious danger to public health, which has been acknowledged by the USA Centers for Diseases Control & Prevention and the European Centre for Disease Prevention and Control. Bacterial vaccines have the potential to reduce community reliance on antibiotics and there is evidence that vaccines can contribute to decreased antibiotic usage.
Absynth has used its technology platform to establish a vaccine pipeline targeting pathogens for substantial markets, in which no marketed vaccines exist. The most advanced vaccine programme targets Staphylococcus aureus, while pipeline vaccine programmes target Clostridium difficile and Streptococcus pyogenes. The Company also has a S. aureus antibody programme in preclinical research. The Company’s approach has the potential to overcome previous limitations through its novel antigens, as well as its innovative approach to using in vivo models and correlates of infection for candidate optimization and selection. Six patent families are filed from which eleven patents have granted.
Dr Fiona MarstonChief Executive
Dr Anthony UptonHead of Development
Appleyard Lees is a highly respected and leading firm of European Patent and Trade Mark Attorneys.
They have an experienced life science and chemical team and an enviable reputation of working with some of the most innovative organisations in the UK and around the world. Acting for a range of clients, including well-known multinational corporations, Universities and SMEs, they have earned a reputation for not only handling complex technical subject matter, but also providing clear and strategic advice.
Appleyard Lees have offices throughout the UK and also in Munich and The Hague. They are listed in Chambers UK, the Legal500 and Managing IP ‘IP Stars’.
Mr Simon BradburyPatent Attorney & Head of Life Sciences
Bionow is the life-sciences membership organisation for the North of England and supports business growth, competitiveness and innovation within the biomedical and life science sectors. Bionow’s membership offering focuses upon the specific needs of firms at their different stages of development, including dedicated business support programmes, shared procurement schemes with significant cost savings, exclusive insurance benefits, recruitment and training services, local and national events and access to a vibrant network of businesses.
Miss Amy WrightBusiness Development Associate
Datatrial is a clinical technology organisation with supporting biometrics services. Our innovative nowEDC™ solution provides data capture, verification and validation, query management, data extract, randomization and real-time reporting in one integrated system. nowEDC is easy-to-use and is highly configurable, making it a natural fit for complex workflows and trial designs.